Several studies have suggested that GSI treatment in T-ALL cell lines with activating Notch1 mutations reduces the levels of the active protein and downregulates Notch target genes, leading to G1 cell cycle arrest and varying degrees of apoptosis [41]. This evidence concerns the gene NOTCH1 and acute lymphoblastic leukemia.